Guselkumab Drug Aliquot | Anti-IL23 | Therapeutic Antibody

Aliquoted from the original reference drug | Now available for research use

Difficult to obtain antibody drugs are now available as research consumables

Tremfya® The reference Guselkumab Drug

Divided into tubes

Guselkumab Drug Aliquots

Aliquots of the reference drug Guselkumab are now available as research consumables.

Guselkumab drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Guselkumab drug can be ordered at the same time. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug. Are you thinking why buy aliquots?

Buy drug aliquot Guselkumab
Easy Access

Easy Access

Easy to order as license-free research consumable
Multiple batches

Multiple batches

Up to 10 batches of original drugs for examining batch-to-batch variations
Reduce costs

Reduce costs

Up to 80% less compared to the original pharmaceutical price
Prompt delivery

Prompt delivery

Shipment within days worldwide according to GDP-standards
Documented origin

Documented origin

Information on batch, registration number, expiry date, GDP-compliant pedigree

What our clients say

Cetuximab / Erbitux

Product Reference

Drug nameErbitux®
INNCetuximab
API typeCetuximab is a chimeric monoclonal IgG1antibody produced in a mammalian cell line (Sp2/0) by recombinant DNA technology
Pharmacotherapeutic group
Antineoplastic agents, monoclonal antibodie
ATC code
L01XC06
Target of antibody
EGFR; Synonyms: C-erb, CG10079, D-EGFR, D-Egf, DEGFR, DER, DER flb, DER/EGFR, DER/faint little ball, DER/top, DER/torpedo, DER1, DEgfr, Degfr, Der, DmHD-33, Dmel\\CG10079, EFG-R, EGFr, EGfr, EK2-6, Egf, Egf-r, EgfR, El, Elp, Elp-1, Elp-B1, Elp-B1RB1, HD-33, TOP, Torpedo/DER, Torpedo/Egfr, c-erbB, d-egf-r, dEGFR, dEGFR1, dEgfr, der, egfr, flb, l(2)05351, l(2)09261, l(2)57DEFa, l(2)57EFa, l(2)57Ea, mor1, top, top/DER, top/flb, torpedo/Egfr, torpedo/egfr, EGFR12, EGFR15, egfr1, Erbb2, ERBB, ERBB1, HER1, PIG61, mENA, ErbB-1, Errp, 9030024J15Rik, AI552599, Erbb, Errb1, Wa5, wa-2, wa2
General function
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Cetuximab is a chimeric monoclonal IgG1 antibody that is specifically directed against the epidermal growth factor receptor (EGFR).
EGFR signalling pathways are involved in the control of cell survival, cell cycle progression, angiogenesis, cell migration and cellular invasion/metastasis.
Cetuximab binds to the EGFR with an affinity that is approximately 5- to 10-fold higher than that of endogenous ligands. Cetuximab blocks binding of endogenous EGFR ligands resulting in inhibition of the function of the receptor. It further induces the internalisation of EGFR, which can lead to downregulation of EGFR. Cetuximab also targets cytotoxic immune effector cells towards EGFRexpressing tumour cells (antibody dependent cell-mediated cytotoxicity, ADCC).
Cetuximab does not bind to other receptors belonging to the HER family. The protein product of the proto-oncogene RAS (rat sarcoma) is a central down-stream signal transducer of EGFR. In tumours, activation of RAS by EGFR contributes to EGFR-mediated increased proliferation, survival and the production of pro-angiogenic factors.
RAS is one of the most frequently activated family of oncogenes in human cancers. Mutations of RAS genes at certain hot-spots on exons 2, 3 and 4 result in constitutive activation of RAS proteins independently of EGFR signaling.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)In both in vitro and in vivo assays, cetuximab inhibits the proliferation and induces apoptosis of human tumour cells that express EGFR. In vitro cetuximab inhibits the production of angiogenic factors by tumour cells and blocks endothelial cell migration. In vivo cetuximab inhibits expression of angiogenic factors by tumour cells and causes a reduction in tumour neo-vascularisation and metastasis.
Original license holder
Marketing authorisation numbers
EU/1/04/281/003
EU/1/04/281/005
Marketing authorisation holder
Merck KGaA
64271 Darmstadt
Germany
Name of the manufacturer of the biological active substance
Merck KGaA
Frankfurter Straße 250
64293 Darmstadt
Germany

Boehringer Ingelheim Pharma GmbH & Co
KG
Birkendorfer Str. 65
88397 Biberach
Germany
Name and address of the manufacturer(s) responsible for batch release
Max shelf life
48 months
Storage conditions
2°C – 8°C
List of excipients
Sodium chloride
Glycine
Polysorbate 80
Citric acid monohydrate Sodium hydroxide
Water for injections